Bcl-2 Expression in Stage III Breast Cancer Patients
Author Information
Author(s): Lee Kyung-Hun, Im Seock-Ah, Oh Do-Youn, Lee Se-Hoon, Chie Eui Kyu, Han Wonshik, Kim Dong-Wan, Kim Tae-You, Park In Ae, Noh Dong-Young, Heo Dae Seog, Ha Sung Whan, Bang Yung-Jue
Primary Institution: Seoul National University College of Medicine
Hypothesis
The study aims to assess the prognostic significance of various biomarkers, including bcl-2, in breast cancer patients treated with specific chemotherapy.
Conclusion
Bcl-2 is an independent prognostic factor of disease-free survival in stage III breast cancer patients.
Supporting Evidence
- Bcl-2 expression was significantly correlated with longer disease-free survival.
- Negative bcl-2 expression was identified as an independent indicator of poorer disease-free survival.
- Patients with bcl-2 expression had a significantly longer disease-free survival than those without.
Takeaway
This study found that a protein called bcl-2 can help predict how well breast cancer patients will do after treatment.
Methodology
The study analyzed clinico-pathologic characteristics and biomarker expressions in 151 stage III breast cancer patients who received specific chemotherapy.
Limitations
The study was conducted at a single institution and included only patients treated with a specific chemotherapy regimen.
Participant Demographics
151 patients (3 male, 148 female) with a median age of 46 years.
Statistical Information
P-Value
p<0.001 for lymph nodes, p=0.002 for bcl-2, p=0.013 for ER
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website